<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164687">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01748097</url>
  </required_header>
  <id_info>
    <org_study_id>IV BIC for IVONCOL</org_study_id>
    <nct_id>NCT01748097</nct_id>
  </id_info>
  <brief_title>Intravenous Bicarbonate To Verify The Correct Position of IV Catheters in Oncological Patients Oncological Patients Receiving Chemotherapy</brief_title>
  <acronym>IVBICONCOL</acronym>
  <official_title>Phase III Study to Assess the Utility of a New Innovative Technique Using Intravenous Bicarbonate to Verify the Correct Position of Patients Scheduled for Intravenous Bicarbonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands: Ministry of Health, Welfare and Sports</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators use bicarbonate injected to an intravenous line and the changes in the
      exhaled end-tidal carbon dioxide to verify whether the IV line is in the vein or surrounding
      tissue
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The method was proved useful in previous phase I, II studies. Now the investigators move on
      to assess the method in a phase III study in oncological patients.

      each patients which will be subjected to intravenous chemotherapy will be eligible ( see
      also inclusion/exclusion criteria).

      Once consent obtained the patient will have an IV line placed. each line placed will be
      categorized by the clinical team into 3 categories:

        1. IV in place ready to use for chemotherapy ( good blood return)

        2. Doubtful position ( no blood return/ little blood return bu flushes well).

        3. IV not in place. Study design Category 1. IV bicarbonate 4.2% 20 cc and NS 20 cc in a
           randomized fashion Category 2. same as above Category 3. No injections
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>change in exhaled end tidal co2</measure>
    <time_frame>1-3 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the injection of bicarbonate in a vein cause a rapid and distinct change in exhaled end-tidal CO2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Detection of the Correct Position of Intravenous Line</condition>
  <arm_group>
    <arm_group_label>IV bicarbonate 4.2% 20 cc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injecting 20cc 4.2% to a newly administered IV line</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>injecting 20 cc normal saline to a newly administered IV line</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium bicarbonate 4.2%</intervention_name>
    <arm_group_label>IV bicarbonate 4.2% 20 cc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-80 oncological disease requires intravenous chemotherapy

        Exclusion Criteria:

          -  1. refusal to participate 2. lung disease acute or chronic sPo2 &lt; 92%, PaCO2 &gt; 50 3.
             renal failure Creatinine &gt; 2 mg% 4. metabolic alkalosis HCO3 &gt; 30 meq/L 5. medication
             that affect bicarbonate levels: Bicarbonate, Diamox, Fusid 6. obesity BMI &gt; 38 7.
             congestive heart failure EF &lt; 40 % or clinical signs of congestive heart failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ilan keidan, MD</last_name>
    <phone>97235302754</phone>
    <email>ilan.keidan@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Clinic</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ilan keidan, MD</last_name>
      <phone>972526669370</phone>
      <email>ilan.keidan@sheba.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center Oncology</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ilan keidan, MD</last_name>
      <phone>07235302754</phone>
      <email>ilan.keidan@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 30, 2012</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ilan Keidan</investigator_full_name>
    <investigator_title>director pediatric anesthesia</investigator_title>
  </responsible_party>
  <keyword>infiltration</keyword>
  <keyword>extravasation</keyword>
  <keyword>sodium bicarbonate</keyword>
  <keyword>capnography</keyword>
  <keyword>end tidal carbon dioxide</keyword>
  <keyword>chemotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
